S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: Updated results from a phase 3 trial

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kim, Tae ^a   Hong, Sang ^b   Lim, Yeong ^a   Lee, Jeeyun ^a   Kim, Won ^b   Kim, Kyu Pyo ^b   Kim, Young ^c   Baek, Yeon ^c   Kim, Hyun ^d   Lee, Keun Wook ^d   Chung, Ik Joo ^e   Cho, Sang Hee ^e   Lee, Hee ^f   Shin, Joon ^g   Kang, Jin ^h   Shin, Bok ⁱ   Lee, Won ^j   Jo, Jung ^k   Park, Suk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Chonnam National University Research Institute of Medical Sciences   (South Korea)

^f Yeungnam University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Korea Institute of Radiation and Medical Science   (South Korea)

ⁱ Gachon University   (South Korea)

^j Korea University   (South Korea)

^k Biostatistics ICON Clinical Research   (South Korea)

more..

Author keywords

Capecitabine; Colorectal cancers; S 1

Indexed keywords

CAPECITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG COMBINATION; FLUOROURACIL; OTERACIL; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; METASTASIS; MIDDLE AGED; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAPECITABINE; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME;

EID: 84924419750     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-883     Document Type: Article

References (27)

1. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004, 15:85-106.
2. Meta-analysis Group In Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 1998, 16:301-308.
3. Cascinu S: Oral treatment for gastric cancer: new choices, better choices? Lancet Oncol 2008, 9:188-189. 10.1016/S1470-2045(08)70042-1
4. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013, 39:60-67. 10.1016/j.ctrv.2012.09.007
5. Pieters A, Laurent S, Dero I, Van Damme N, Peeters M: The role of oral fluoropyrimidines in the treatment of advanced gastric cancer. Acta Gastroenterol Belg 2008, 71:361-366.
6. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004, 22:2084-2091. 10.1200/JCO.2004.11.069
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
8. Maehara Y: S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003,6(Suppl 1):2-8.
9. Yamada Y, Tahara M, Miya T, Satoh T, Shirao K, Shimada Y, Ohtsu A, Sasaki Y, Tanigawara Y: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer 2008, 98:1034-1038. 10.1038/sj.bjc.6604271
10. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 2009, 20:892-896. 10.1093/annonc/mdn721
11. Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 2012, 13:1125-1132. 10.1016/S1470-2045(12)70363-7
12. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L: XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011, 105:58-64. 10.1038/bjc.2011.201
13. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008, 19:1720-1726. 10.1093/annonc/mdn370
14. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019. 10.1200/JCO.2007.14.9930
15. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ: A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008, 99:584-590. 10.1038/sj.bjc.6604536
16. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC: A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012, 48:518-526. 10.1016/j.ejca.2011.12.017
17. Seol YM, Song MK, Choi YJ, Kim GH, Shin HJ, Song GA, Chung JS, Cho GJ: Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study. Jpn J Clin Oncol 2009, 39:43-48.
18. Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, Ura T, Tajika M, Niwa Y, Muro K: A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol 2013, 18:539-546. 10.1007/s10147-012-0416-6
19. Zhang X, Cao C, Zhang Q, Chen Y, Gu D, Shen Y, Gong Y, Chen J, Tang C: Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis. PLoS One 2014, 9:e84230. 10.1371/journal.pone.0084230
20. Petrelli F, Barni S: Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol 2013, 24:186-192. 10.1093/annonc/mds289
21. Zietemann VD, Schuster T, Duell TH: Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. J Thorac Dis 2011, 3:88-98.
22. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, Tabata M, Tanimoto M: Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PLoS One 2011, 6:e26646. 10.1371/journal.pone.0026646
23. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649. 10.1093/jnci/djp369
24. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012. 10.1200/JCO.2007.14.9898
25. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
26. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
27. Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K: Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013, 14:1278-1286. 10.1016/S1470-2045(13)70490-X